Imbruvica revenue guidance
AbbVie (ABBV) expects Imbruvica to contribute ~$3.3 billion in revenue in 2018, including $2.7 billion worth of sales contributions from the US market.
Imbruvica is co-marketed by AbbVie and Johnson & Johnson (JNJ). To know more about Imbruvica, read AbbVie Expects Peak Sales of $7 Billion for Imbruvica.
Imbruvica’s 2017 performance
In 4Q17, Imbruvica reported sales of $708 million for AbbVie, a YoY (year-over-year) rise of ~39% on both an operational and a reported basis. The drug also reported US market sales of $585 million, a YoY rise of ~35.3%. In 4Q17, international markets contributed ~$123 million to Imbruvica’s sales attributable to AbbVie, a YoY rise of ~58% on both an operational and a reported basis.
For 2017, the company reported Imbruvica revenue of close to $2.6 billion, a YoY rise of 41% on both an operational and a reported basis. The drug earned revenue of close to $2.1 billion in the US market, a YoY rise of ~36%. In 2017, international markets contributed ~$429 million to Imbruvica’s sales attributable to AbbVie, a YoY rise of ~70% on both an operational and a reported basis.
Imbruvica’s robust revenue performance in 2017 was mainly attributable to its market-leading position across all lines of therapy in the chronic lymphocytic leukemia (or CLL) segment. In 2017, Imbruvica also managed to secure approval from the FDA in two more hematologic oncology indications, including chronic graft-versus-host disease and marginal zone lymphoma.
AbbVie is also exploring Imbruvica as a monotherapy or in combination regimens in several other hematologic oncology indications such as multiple myeloma, non-Hodgkin’s lymphoma, acute myeloid leukemia, and CLL. Imbruvica is thus expected to enable AbbVie to compete effectively with other hematologic oncology players such as Novartis (NVS) and Celgene (CELG).
In the next article, we’ll discuss AbbVie’s oncology drug, Venclexta, in greater detail.